Skip to main content

Atropos Health Named to the 2025 CB Insights’ List of the 50 Most Promising Digital Health Startups

Atropos Health is Recognized for its Achievements in Real World Evidence Generation

CB Insights today named Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, to its seventh annual Digital Health 50, showcasing the 50 most promising private digital health companies in the world.

“The 2025 Digital Health 50 winners are high-momentum companies poised to define the next era of healthcare,” said Ellen Knapp, Principal Analyst at CB Insights. “This year’s cohort is advancing the shift from reactive to proactive care, developing AI solutions tailored to healthcare's unique regulatory environment, and addressing critical sector-wide challenges from care access to provider burnout and workforce shortages.”

“Atropos Health is proud to be part of the CB Insights Digital Health 50 list as we continue to drive the adoption of real-world evidence in clinical use for patient care and research,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Being recognized among many other pioneering companies is an honor and motivation to continue our work of utilizing real-world evidence to help healthcare systems and life sciences organizations make faster, more informed decisions that improve outcomes.”

The list primarily includes early- and mid-stage startups driving innovation across digital health. Our research team picked winning companies based on CB Insights datasets, including deal activity, industry partnerships, team strength, investor strength, employee headcount, and proprietary Commercial Maturity and Mosaic scores. We also dug into Analyst Briefings submitted directly to us by startups.

Atropos Health is the pioneer in translating real-world clinical data into high-quality, personalized evidence for care. Atropos Health answers questions with both existing evidence and offers the option to generate new evidence. With over 100,000 novel studies, doctors and researchers find more answers to clinical questions not available in existing published literature when utilizing Atropos Health. Plus, Atropos Health evaluates every answer and surfaces a ranking for users - a green, yellow or red “badge” - to indicate whether the question was “Answered with Evidence.” The methodologies and test results demonstrating that a green badge can be achieved 94% of the time with Atropos Health were published earlier this year.

Atropos Health has also joined forces with leading life science companies, like Novartis for precision medicine initiatives, helping clinicians more accurately identify undiagnosed patients with a rare disease, paroxysmal nocturnal hemoglobinuria, via an AI model built, trained and deployed via the Atropos Evidence™ Network.

Most recently, Atropos Health partnered with Stanford Health Care and is collaborating with Microsoft to surface personalized evidence within the clinical workflow. The Atropos Evidence™ Agent takes patient history and data from ambient AI to surface personalized evidence for their patient within the EHR at the moment of treatment decision. Without even asking a question, clearly summarized evidence from literature and guidelines as well as novel patient-specific real-world evidence, is presented to them at the point of care.

Quick facts on the 2025 Digital Health 50:

  • The 50 winners span categories such as care delivery, revenue cycle management, drug discovery & development, and diagnostics.
  • This year's cohort is deploying AI across a wide variety of use cases, with notable adoption of agentic AI, voice AI, and automated provider workflows.
  • Collectively raised $2B in equity funding in 2025 YTD (as of 10/14/2025).
  • 52% are early-stage companies (seed/angel or Series A funding).
  • Established 140+ business relationships since 2024 with industry leaders including Cleveland Clinic, IBM, and Novartis.

About CB Insights

CB Insights is the leader in predictive intelligence on private companies. It delivers instant insights that help you source and analyze private companies, focus on the right markets, and stay ahead of competitors. Our AI agents are powerful because they translate signals into the exact outputs your teams need to move first — defensible, sourced, and board-ready. To learn more, please visit www.cbinsights.com.

About Atropos Health

Atropos Health is the developer of GENEVA OS®, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  262.77
+0.53 (0.20%)
AMD  238.03
-2.53 (-1.05%)
BAC  51.52
-0.52 (-1.00%)
GOOG  251.34
-5.68 (-2.21%)
META  733.27
+1.10 (0.15%)
MSFT  517.66
+0.87 (0.17%)
NVDA  181.16
-1.48 (-0.81%)
ORCL  275.15
-2.03 (-0.73%)
TSLA  442.60
-4.83 (-1.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.